Comparison of the effect of Adalimumab and Methotrexate in the treatment of psoriasis

Comparison of the efficacy of Adalimumab and Methotrexate in cases of moderate to sever of psoriasis, a double-blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100102002954N26

Enrollment

Registered

2022-02-28

Start date

2022-03-01

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to sever of psoriasis. Generalized pustular psoriasis

Interventions

Intervention 1: Intervention group: For patients in the intervention group, in addition to routine treatment (including the use of glycerin topical lotion 10% and 25 mg hydroxyzine tablets three time

Eligibility

Sex/Gender

All

Age

15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Age range 55-15 years; Patients with a definite diagnosis of moderate to severe psoriasis; Having the satisfaction of participating in the project.

Exclusion criteria

Exclusion criteria: History of severe burns or skin damage; Existence of severe chronic hormonal disorders such as hypothyroidism; History of severe hirsutism; History of topical treatment of psoriasis with drugs and combined solutions in the last six months; History of skin laser in the past year; History of chronic liver and kidney disease; History of hormone therapy (estrogen or testosterone), Pregnancy or lactation,

Design outcomes

Primary

Measure	Time frame
Measurement of psoriasis severity index. Timepoint: Beginning and end of the study. Method of measurement: Psoriasis Severity Index Calculator Software Version 1.7.2.;Measure the percentage of surface area involved in the patient's body. Timepoint: Beginning and end of the study. Method of measurement: Calculated with the formula of the percentage of surface area involved in the patient's body.;Measurement of redness of psoriasis rash. Timepoint: Beginning and end of the study. Method of measurement: Observation and clinical examination.	—

Measure

Time frame

Measurement of psoriasis severity index. Timepoint: Beginning and end of the study. Method of measurement: Psoriasis Severity Index Calculator Software Version 1.7.2.;Measure the percentage of surface area involved in the patient's body. Timepoint: Beginning and end of the study. Method of measurement: Calculated with the formula of the percentage of surface area involved in the patient's body.;Measurement of redness of psoriasis rash. Timepoint: Beginning and end of the study. Method of measurement: Observation and clinical examination.

—

Secondary

Measure	Time frame
Measurement of the rash protrusion of psoriasis. Timepoint: Beginning and end of the study. Method of measurement: Observation and clinical examination.;Measuring the extent of scaling of the psoriasis rash. Timepoint: Beginning and end of the study. Method of measurement: Observation and clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fateme Torabi

Shahroud University of Medical Sciences

ftrb4524@gmail.com+98 23 3234 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026